Who are the patients with early arthritis with worse than death scores on the EQ-5D? Results from the ESPOIR cohort

Rheumatology (United Kingdom)

Volumn 52, Issue 5, 2013, Pages 832-838

  Gaujoux Viala, Cécile ^a,b,c   Fautrel, Bruno ^b,c   Guillemin, Francis ^a,b,c,d   Flipo, René Marc ^e   Bourgeois, Pierre ^b,c   Rat, Anne Christine ^a,d  

^a UNIVERSITÉ DE LORRAINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d INSERM   (France)

^e UNIV LILLE   (France)

Author keywords

Early arthritis; EQ 5D; Pain; Utility

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ANXIETY; ARTHRITIS; ARTICLE; DEATH; DEPRESSION; DISABILITY; DISEASE ACTIVITY; DISEASE SEVERITY; EDUCATIONAL STATUS; EQ 5D QUESTIONNAIRE; FATIGUE; FEMALE; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH STATUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36;

ADAPTATION, PHYSIOLOGICAL; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DISABILITY EVALUATION; EARLY DIAGNOSIS; FEMALE; HUMANS; ILLNESS BEHAVIOR; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAIN MEASUREMENT; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

EID: 84876707891     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes270     Document Type: Article

References (18)

1. Harrison MJ, Bansback NJ, Marra CA, Drummond M, Tugwell PS, Boonen A. Valuing health for clinical and economic decisions: directions relevant for rheumatologists. J Rheumatol 2011;38:1770-5.
2. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716-21.
3. Tsuchiya A, Dolan P. The QALY model and individual preferences for health states and health profiles over time: a systematic review of the literature. Med Decis Making 2005;25:460-7.
4. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
5. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
6. Khanna D, Tsevat J. Health-related quality of life-an introduction. Am J Manag Care 2007;13(Suppl 9): S218-23.
7. Combe B, Benessiano J, Berenbaum F et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007;74: 440-5.
8. Prevoo ML, van 't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
9. Fries JF, Spitz P, Kraines RG et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23: 137-45.
10. Barton GR, Sach TH, Avery AJ et al. A comparison of the performance of the EQ-5D and SF-6D for individuals aged >or= 45 years. Health Econ 2008;17:815-32.
11. Chevalier J, de Pouvourville G. Valuing EQ-5D using Time Trade-Off in France. Eur J Health Econ 2011 Sep 21, [Epub ahead of print] doi:10.1007/s10198-011-0351-x.
12. Macran S, Kind P. 'Death' and the valuation of health-related quality of life. Med Care 2001;39:217-27.
13. De Wit GA, Busschbach JJV, De Charro FT. Sensitivity and perspective in the valuation of health status: whose values count? Health Econ 2000;9:109-26.
14. Harrison MJ, Davies LM, Bansback NJ et al. Why do patients with inflammatory arthritis often score states 'worse than death' on the EQ-5D? An Investigation of the EQ-5D classification system. Value Health 2009;12: 1026-34.
15. Adams R, Walsh C, Veale D et al. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis. Pharmacoeconomics 2010;28:477-87.
16. Badia X, Roset M, Herdman M, Kind PA. Comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Making 2001;21:7-16.
17. Tsuchiya A, Ikeda S, Ikegami N et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ 2002;11:341-53.
18. Apolone G, De Carli G, Brunetti M, Garattini S. Health-related quality of life (HR-QOL) and regulatory issues. An assessment of the EMEA recommendations on the use of HR-QOL measures in drug approval. Pharmacoeconomics 2001;19:187-95.